Close Menu

NEW YORK – Meridian Bioscience reported on Thursday that its fiscal fourth quarter revenues decreased 4 percent due to competitive pressures in the diagnostics market and pricing declines in its gastrointestinal products.

For the three months ended Sept. 30, the firm reported revenues of $50.8 million down from $53.1 million a year ago. It still beat the average consensus Wall Street estimate of $50.6 million.

Meridian reported Q4 diagnostics revenues of $33.4 million, down 9 percent year over year from $36.8 million. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.